Overview
MindMed Q3 net loss widens to $67.3 mln, driven by increased R&D and G&A expenses
Company completed public offering, raising $242.8 mln in net proceeds
Result Drivers
PUBLIC OFFERING - Completed public offering raised $242.8 mln in net proceeds, strengthening financial position
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.78
Q3 Net Income
-$67.3 mln
Q3 Basic EPS
-$0.78
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Mind Medicine (MindMed) Inc is $21.00, about 45.1% above its November 5 closing price of $11.53
Press Release: ID:nBw19QgRRa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
